Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of crushed Triumeq with or without drip feed versus whole tablet
NL-OMON42415Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of abacavir, dolutegravir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by Ziekenhuisapotheek. Primary endpoints: Bioequivalence of whole tablet versus crushed and suspended tablet and Bioequivalence of whole tablet versus drip feed plus crushed and suspended tablet. Started Apr 2016; status: active, not recruiting.
02
Drugs
abacavirdolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON42415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42415.